MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammation

Journal of Investigative Dermatology

Volumn 111, Issue 1, 1998, Pages 77-82

  Zunic, Melita ^a   Bahr, George M ^b   Mudde, Geert C ^a   Meingassner, Josef G ^a   Lam, Charles ^a  

^a Brunnerstra e 59   (Austria)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Contact dermatitis

Indexed keywords

3 O [N ACETYLMURAMYLLYSYL ISO] 2 DI ON GLYCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MURAMYL DIPEPTIDE DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXAZOLONE; PHORBOL ESTER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SKIN ALLERGY; SKIN INFLAMMATION; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION;

EID: 0031833310     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00249.x     Document Type: Article

References (51)

1. Adeleye TA, Moreno C, Ivanyi J, Aston R: The modulation of tumor necrosis factor-α. interleukin-1α and glucose levels with GMDP and other analogues of muramyl dipeptide. APAUS 102:145-152, 1994
2. Ahlfors E, Jonsson R, Czerkinsky C: Experimental T cell mediated inflammatory reactions in the murine oral mucosa, H. Immunohistochemical characterization of resident and infiltrating cells. Clin Exp Immunol 104:297-305, 1996
3. Andrew PJ, Harant H, Lindley IJ: Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level. Biochem Biophys Res Commun 25:949-956, 1995
4. d mast cell deficient mice. J Immunol 132:2687-2694, 1983
5. Auci DL Chice SM, Dukor P, Durkin HG: Control of IgE responses. II Isotype specific suppression of peak hapten specific IgE antibody forming cell responses in BPO-KLH sensitized mice after oral administration of inuramyldiptide or murabutide. Immunopharmacol 26:157-169, 1993
6. Bahr MG, Pouillart PR, Chedid L: Enhancement in vivo of the antiinflammatory and antitumor activities of type I Interferon by association with the synthetic immunomodulator murabutide. J Inter Cyt Res 16:297-306, 1996
7. + normal human keratinoytes. J Clin Invest 93:2275-2279, 1994
8. Breathnach SM: Drug reactions. In: Champion RH, Burton JL, Ebling FJG (eds.). Textbook of Dermatology. 5th edn. Blackwell Scientific, Oxford, 1992, pp. 2961-3036
9. Cua DJ, Hinton DR, Kirkman L, Stohlman SA: Macrophages regulate induction of delayed-type hypersensitivity and experimental allergic encephalomyelitis in SJL mice. Eur J Immunol 25:2318-2324, 1995
10. Drapier JC, Wietzerbin J, Hibbs JB Jr: Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanisin in macrophages. Eur J Immunol 18:1587-1592, 1988
11. Dugas B, Mossalayi MD, Damais C, Kolb JP: Nitric oxide production by human monocytes: evidence for a role of CD23. Immunol Today 16:574-580, 1995
12. Eigler A, Sinha B, Endres S: Nitric oxide-releasing agents enhance cytokine-induced tumor necrosis factor synthesis in human mononuclear cells. Biochem Biophys Res Commun 196:494-501, 1993
13. 15N]nitrate in Biological fluids. Anal Biochem 126:131-138, 1982
14. Hay RJ, Chamipion RH, Greaves MW: Systeimc therapy In: Champion RH, Burton JI, Ebling FJG (eds.) Texbook of Dermatology, 5th edn. Blackwell Scientific, Oxford, 1992, pp. 1391-1458
15. Heutler C, Lopar G, Koch F, Iiokenbacher B, Kampgen L, Romani N, Schuler G: Cytokine gene expression in murine epidermal cell suspensions: interleukin 1β and macrophage inflmatory protein 1 are selectively expressed in Langerhans cells but are differentially regulated in culture. J Exp Med 176:1221-1226, 1992
16. Ialenti A, Ianaro A, Moncada S, Di Rosa M: Modulation of acute inflammation by nitric oxide. Eur J Pharmacol 211:177-182, 1992
17. Kolb H, Kolb-Bachofen V: Nitric oxide: a patogenic factor in autoimmunity. Immunol Today 13:157-160, 1992
18. Kondo S, Pastore S, Shivji GM, Mckenzic RC, Sauder DN: Characterisation of epidermal cytokine profiles in seinsitization and elicitation phases of allergic contact dermatitis as well as uritant contact dermatitis in mouse skin. Cytokine Res 13:367-375, 1994
19. Koprowsky H, Zheng YM, Heber-Katz E, et al: In vivo expression of inducible nitric oxide synthase in experimental induce neurologic disease. Proc Natl Acad Sci USA 90:3024-3027, 1993
20. Krasnow SW, Zhang IQ, Leung KY, Osborn L, Kunkel S, Nabel GJ: Tumor necrosis factor-alpha, interleukin 1, and phorbol myristate acetate are independent activators of NF-kappa B which differentially activate T cells. Cytokine 3:372-379, 1991
21. Kricek F, Zunic M, Ruf C, de Jong G, Dukor P, Bahr GM: Suppression of in vivo IgE and tissue II-4 mRNA induction by SDZ 280,636, a synthetic muramyl dipeptide derivative. Immunopharmacol 36:27-39, 1997
22. Kurimoto I, van-Rodijen N, Dijkstra CD, Streilein JW: Role of phagocytic macrophages in induction of contact hypersensitivity and tolerance by hapten applied to normal and ultraviolet B-irradiated skin. Immunology 83:281-287, 1994
23. Lam C, Schütze E, Quakyi E, Liehl E, Stütz P: SDZ MRL 953, a novel synthetic lipid A analogue, induces tolerance to the lethal effects of endotoxin and enhances nonspecific immunity. Can J Infect Dis 3:94B-100B, 1992
24. Martin E, Nathan C, Xic QW: Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J Exp Med 180:977-984, 1994
25. Matsue H, Cruz PD Jr, Bergstresser PR, Takashima A: Profiles of cytokine mRNA expressed by dendritic epidemal T cells in mice. J Dermatol 101:537-542, 1993
26. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF, Wahl SM: Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 178:749-754, 1993
27. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137:568-576, 1997
28. Mihatsch MJ, Wolff K: Consensus conference on cyclosporin A for psoriasis, February 1992. Br J Dermatol 126:621-623, 1992
29. Morita H, Hori M, Kitano Y: Modulation of Picrylcloride-induced contact hypersensitivity reaction in mice by nitric oxide. J Invest Dermatol 107:549-552, 1996
30. Mossalayi MD, Paul-Eugène N, Ouaaz F, et al: Involvement of FcεRII/CD23 and 1-arginine-dependent pathway in IgE-mediated stimulated of human monocyte functions. Int Immunol 6:931-934, 1994
31. Ohmen JD, Hamfin JM, Nickoloff BJ, et al: Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 154:1956-1963, 1995
32. Palacios M, Knowles RG, Moncada S: Enhancers of nonspecific immunity induce nitric oxide synthase: induction does not correlate with toxicity or adjuvancy. Eur J Immunol 2:2303-2307, 1992
33. Parant MA, Pouillart P, Le Contel C, Parant FJ, Chedid LA, Bahr GM: Selective modulation of lipopolysaccharide-induced death and cytokine production by various inuramyl peptides. Infections Immunity 63:110-113, 1995
34. Qureshi AA, Lerner LH, Lerner EA: From bedside to the bench and back: nitric oxide and the cutis, Arch Dermatol 132:889-893, 1996
35. Raederstorff D, Pantze M, Bachmann Moser U: Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Int Arch Allergy Immunol 111:284-290, 1996
36. Robertson DB, Maibach HI: Adverse systemic effects of topical corticoids. In: Maibach HI, Surber C (eds.). Topical Corticosteroids, Karger, Basel, 1992, pp. 163-169
37. Sauder DN: The role of epidermal cytokines in inflammatory diseases. J Invest Dermatol 95:27s, 1990
38. Schreck R, Bevec D, Dukor P, Baeuerle PA, Chedid L, Bahr GM: Selection of a muramyl peptide based on its lack of activation of nuclear factor-κB as a potential adjuvant for AIDS vaccines. Clin exp Immunol 90:188-193, 1992
39. Schreiber S, Kilgus O, payer E, Kutil R, Elbe A, Mueller C, Stingl G: Cytokine pattern of Langerhans cells isolated from murine epidermal cell culture. J Immunol 149:3525-3534, 1992
40. Shi F, Kurzman ID, MacEwen EG: In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysacchaide in normal dogs. Cancer Biother 10:317-325, 1995
41. Silverman DHS, Wu H, Karnowsky ML: Muramyl peptides and serotonine interact at specific binding sites on macrophages and enhance superoxide release. Biochem Biophys Res Commun 131:1160-1167, 1985
42. Staite ND, Justen JM, Sly LM, Beaudet AL, Bullard DC: Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin. Blood 88:2973-2979, 1996
43. 125I-labeled aryl-azide derivatives of muramyldipeptide. Int J Immunopharmacol 11:653-661, 1989
44. h1 response in situ: An immunocytochemical study. J Allergy Clin Immunol 97:828-837, 1996
45. Tsuji RF, Geba GP, Wang Y, Kawamoto K, Matis LA, Askenase PW: Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells. J Exp Med 186:1015-1026, 1997
46. Vermeulen MW, David JR, Remold HG: Differential mRNA responses in human macrophages activated by interferon-γ and muramyl dipeptide. J Immunol 139:1-7, 1987
47. Wahl SM, Wahl LM, McCarthy JB, Chedid L, Mergenhagen SE: Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol 122:2226-2231, 1979
48. Werfel T, Morita A, Grewe M, Renz H, Wahn U, Kurtmann Kapp A: Allergen specificity of skin infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 107:871-876, 1996
49. Zachariae COC, Thestrup-Pedersen K, Matsushima K: Expression and secretion of leukocyte chemotactic cytokines by normal human melanocytes and melanoma cells. J Invest Dermatol 97:593-599, 1991
50. Zinetti M, Fantuzzi G, Delgado R, Di Santo E, Ghezzi P, Fratelli M: Endogenous nitric oxide production by humaqn monocytic cells regulates LPS-induced TNF production. Eur Cytokine Netw 6:45-48, 1995
51. Zunic M, Kricek F, Dukor P, Bahr GM: Oral administration of muramyl dipeptide (MDP) into mice modulates cell proliferation, immunoglobulin synthesis and cytokine mRNA levels in gut associated lymphoid tissues, Int J Immunopharmac 18:155-162, 1992